Skip to main content

Advertisement

Table 2 Summary of treatment-related events

From: Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study

System organ class /Preferredterm Quetiapine XR N = 23 Placebo N = 13
Subjects with at least 1 related adverse event 17 (47%) 10 (28%)
Eye disorders 0 (0%) 1 (3%)
Vision blurred 0 (0%) 1 (3%)
Gastrointestinal disorders 9 (25%) 4 (11%)
Constipation 3 (8%) 2 (6%)
Dry mouth 7 (19%) 2 (6%)
Nausea 1 (3%) 0 (0%)
Vomiting 1 (3%) 0 (0%)
Investigations 3 (8%) 4 (11%)
Blood pressure increased 0 (0%) 1 (3%)
Glycosylated haemoglobin increased 0 (0%) 1 (3%)
Weight increased 3 (8%) 3 (8%)
Metabolism and nutrition disorders 2 (6%) 2 (6%)
Increased appetite 2 (6%) 2 (6%)
Nervous system disorders 11 (31%) 5 (14%)
Dizziness 4 (11%) 1 (3%)
Headache 1 (3%) 1 (3%)
Memory impairment 0 (0%) 1 (3%)
Restless legs syndrome 0 (0%) 1 (3%)
Sedation 3 (8%) 1 (3%)
Somnolence 4 (11%) 1 (3%)
Tremor 1 (3%) 1 (3%)
Renal and urinary disorders 1 (3%) 1 (3%)
Dysuria 1 (3%) 1 (3%)
Reproductive system and breast disorders 0 (0%) 1 (3%)
Oligomenorrhoea 0 (0%) 1 (3%)
Skin and subcutaneous tissue disorders 0 (0%) 1 (3%)
Rash papular 0 (0%) 1 (3%)